Malvern’s BioTelemetry is providing cardiac monitoring services for the recently launched Apple Heart Study, writes John George for the Philadelphia Business Journal.

“We are extremely excited to be participating in this potentially groundbreaking study,” said Joseph H. Capper, the president and CEO of BioTelemetry. “The Apple initiative will potentially benefit countless individuals who are unaware that they may be at risk for serious health issues.”

The study evaluates the use of the Apple Watch and an accompanying app in discovering irregular heart rhythms. It uses Apple Watch’s heart sensors to gather data and alerts users who might be experiencing atrial fibrillation, a type of cardiac arrhythmia.

[uam_ad id=”58459”]

Advertisement

Cardiac arrhythmia is a group of conditions where beating of the heart is irregular, either too fast or too slow. While majority of arrhythmia types are not considered serious, some lead to complications that include stroke or heart failure. Others can cause cardiac arrest.

BioTelemetry specializes in medical technology – mobile and wireless – that is used for remote cardiac monitoring, mobile blood glucose monitoring, and centralized medical imaging. The company also manufactures original equipment for the healthcare and clinical research industries.

Read more about the study in the Philadelphia Business Journal here, and check out previous VISTA Today coverage of BioTelemetry here.

[uam_ad id=”69715″]